Bioethics Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-12-2024
- Paid Up Capital ₹ 0.10 M
as on 21-12-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 75.03%
(FY 2020)
- Profit 8.88%
(FY 2020)
- Ebitda -126.94%
(FY 2020)
- Net Worth 128.86%
(FY 2020)
- Total Assets 65.67%
(FY 2020)
About Bioethics Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ravinder Kumar, Hira Lal, and Rekha Rani serve as directors at the Company.
- CIN/LLPIN
U24297HR2013PTC048626
- Company No.
048626
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Mar 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bioethics Lifesciences Private Limited offer?
Bioethics Lifesciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Sexual Wellness Products, Female Hygiene Products & Test Kits, Essential & Aromatic Oils, Herb Oil, Cardiovascular Drugs & Medication, Kidney Drugs.
Who are the key members and board of directors at Bioethics Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravinder Kumar  | Director | 22-Mar-2013 | Current |
| Hira Lal | Director | 22-Mar-2013 | Current |
| Rekha Rani | Director | 27-Aug-2024 | Current |
Financial Performance of Bioethics Lifesciences.
Bioethics Lifesciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 75.03% increase. The company also saw a slight improvement in profitability, with a 8.88% increase in profit. The company's net worth Soared by an impressive increase of 128.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioethics Lifesciences?
In 2020, Bioethics Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioethics Lifesciences?
Unlock and access historical data on people associated with Bioethics Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioethics Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioethics Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
